SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00813514

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Does VEGF or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With CNV?

Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component. Most importantly a genetic polymorphism in the gene encoding for the complement factor H (CFH) has been recently identified which is highly associated with an increased risk of developing AMD. This Tyr402His polymorphism located on chromosome 1q31 has been implicated to play a role in the development of the disease. For this purpose a total of 200 patients with wet AMD will be included in the study. As described in detail below, the current study aims to identify potentially non-responders to anti-VEGF therapy based on genetic analysis of VEGF polymorphism and complement factor H polymorphism.

NCT00813514 Choroidal NeoVascularization Age-Related Macular Degeneration
MeSH:Macular Degeneration Choroidal Neovascularization Neovascularization, Pathologic

1 Interventions

Name: VEGF genotyping

Description: blood sample for gene analysis
Type: Genetic
Group Labels: 1

1


Primary Outcomes

Measure: Visual acuity using ETDRS charts

Time: 2 x 5 minutes

Measure: Central retinal thickness (Optical coherence tomography)

Time: 2 x 20 minutes

Measure: VEGF genotyping

Time: 1 week

Purpose: Diagnostic

Allocation: N/A

Single Group Assignment


There is one SNP

SNPs


1 Y402H

This Tyr402His polymorphism located on chromosome 1q31 has been implicated to play a role in the development of the disease. --- Tyr402His ---



HPO Nodes